This article points out some of the concerns with Moderna's release yesterday. Including the fact that their partners on this vaccine - National Institute for Allergy and Infectious Diseases - declined comment, even though they usually want to publicize their successes.
From the linked article:
"Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

"But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be."